Ramipril
- TRADE NAMES: Altace (Monarch); Tritace (Sanofi-Aventis)
- INDICATIONS: Hypertension
- CLASS: Angiotensin-converting enzyme (ACE) inhibitor, Antihypertensive, Vasodilator
- HALF-LIFE: 2–17 hours
Alcohol, Aldesleukin, Allopurinol, Alpha blockers, Alprostadil, Amifostine, Amiloride, Angiotensin II receptor antagonists, Antacids, Antihypertensives, Antipsychotics, Azathioprine, Baclofen, Beta blockers, Calcium channel blockers, Clonidine, Corticosteroids, Cyclosporine, Diazoxide, Diuretics, Eplerenone, Estrogens, Everolimus, General anesthetics, Gold & Gold Compounds, Heparins, Hydralazine, Hypotensives, Insulin, Levodopa, Lithium, MAO inhibitors, Metformin, Methyldopa, Minoxidil, Moxisylyte, Moxonidine, Nitrates, Nitroprusside, NSAIDs, Pentoxifylline, Phosphodiasterase 5 inhibitors, Potassium salts, Prostacyclin analogues, Quinine, Rituximab, Sirolimus, Spironolactone, Sulfonylureas, Telmisartan, Temsirolimus, Tizanidine, Tolvaptan, Triamterene, Trimethoprim
PREGNANCY CATEGORY: D
category C in first trimester; category D in second and third trimesters
Contra-indicated in patients with a history of angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema.
FETAL TOXICITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Page last updated 09/26/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric